bioRxivImmunologyPreprint
Mathematical Modelling Indicates Th-cell Targeted Antibody-Dependent Cellular Cytotoxic Is a Crucial Obstacle Hurdling HIV Vaccine Development
Z. Xu, Q. Zeng, D. Yang, X. Sun, D. Wei, J. Demongeot, Z. Cao
Abstract
HIV poses a significant threat to human health. Although some progress has been made in the development of an HIV vaccine, there is currently no reported success in achieving an effective and fully functional vaccine for HIV. This highlights the challenges involved in HIV vaccine development. Through mathematical modeling, we have conducted a systematic study on the impact of antibody-dependent cellular cytotoxicity (ADCC) on HIV-specific immune responses. Unlike other viral infections, the ADCC effect following HIV infection may cause significant damage to the follicular center Th cells, leading to apoptosis of follicular center cells and rapid death of effector Th cells. This impedes the generation of neutralizing antibodies and creates barriers to viral clearance, thereby contributing to long-term infection. Another challenge posed by this effect is the substantial reduction in vaccine effectiveness, as effective antigenic substances such as gp120 bind to Th cell surfaces, resulting in the apoptosis of follicular center Th cells due to ADCC, hindering antibody regeneration. To address this issue, we propose the concept of using bispecific antibodies. By genetically editing B cells to insert the bispecific antibody gene, which consists of two parts-one targeting the CD4 binding site of HIV, such as the broadly neutralizing antibody 3BNC117, and the other targeting antibodies against other viruses, such as the spike protein of SARS-CoV-2-we can simultaneously enhance the levels of two pathogen-specific antibodies through stimulation with non-HIV-antigens corresponding to the other part of the chimeric antibody, such as the spike protein. This study contributes to the elucidation of the pathophysiology of HIV, while also providing a theoretical framework for the successful development of an HIV vaccine.
- organism: human
- research focus: host-pathogen & immune response
- research focus: drug response / drug discovery
- research focus: benchmarking
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Title: Combinatorial bnAb and T Cell Immunization Enhances Post-Infection Control of SHIVSF162p3 Viremia in Rhesus Macaques
Diane G Carnathan, Chiamaka A Enemuo, … George K Lewis·bioRxiv·Nov 5, 2026
- Development of antibody-dependent cell cytotoxicity function in HIV-1 antibodies
L. E. Doepker, S. Danon, … J. Overbaugh·bioRxiv·Sep 24, 2020
- Mucosal immune stimulation with HSV-2 and polyICLC boosts control of viremia in SIVΔNef vaccinated rhesus macaques with breakthrough SIV infection
M. Aravantinou, O. Mizenina, … N. Derby·bioRxiv·Jun 2, 2020
- Viral load-driven systemic immune exhaustion is an enabler of antibody breadth in HIV infection
Izumi de los Rios Kobara, Uma M. Mangalanathan, … Catherine A. Blish·bioRxiv·Jun 17, 2026
- Effects and mechanisms of monoclonal and polyclonal human antibodies in protection of humanized mice from HIV-1 challenge
Urjeet S. Khanwalkar, Jennifer L. Fields, … Margaret E. Ackerman·bioRxiv·Nov 12, 2025
- Protection from viral rebound after therapeutic vaccination with an adjuvanted DNA vaccine is associated with SIV-specific polyfunctional CD8 T cells in the blood and mesenteric lymph nodes
H. C. Tunggal, P. V. Munson, … D. H. Fuller·bioRxiv·Sep 16, 2020